We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New, Easy-To-Use CRISPR-Based HIV Test Kit to Deliver Results in Minutes

By LabMedica International staff writers
Posted on 11 Jul 2024

With 1. More...

3 million new HIV cases and 630,000 HIV-related deaths reported in 2022 by the World Health Organization, improving and simplifying HIV detection in patients is crucial for reducing outbreaks and the resultant deaths. Although home testing kits for various health conditions have gained popularity, advancements in HIV testing have been slower to develop. Traditional HIV tests typically only become effective several weeks post-infection, raising the risk of unintentional virus transmission. Now, an innovative HIV-detection test kit utilizing advanced CRISPR technology is under development and could act as an early-warning system, potentially saving millions of lives.

CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, represents a breakthrough in genetic engineering, allowing selective modifications to the DNA of organisms in lab environments. This technology leverages genome editing systems that occur naturally in bacteria. A research team at the University of Florida (Gainesville, FL, USA) is nearing completion of their HIV detection method that employs CRISPR technology. Promising rapid results, this test could enable earlier treatment for patients, potentially reducing viral loads to undetectable levels.

The innovative CRISPR-based kit is designed to measure HIV RNA levels quickly using a compact microfluidic device. This palm-sized prototype facilitates rapid self-testing soon after potential exposure, delivering results within minutes. With additional development, this self-testing kit could be available for use in various settings, including homes, doctor's offices, community clinics, and outreach locations like homeless shelters, within the next five years. The team's initial research into this HIV testing method has yielded encouraging results.

“Our goal is to develop a test kit that is not only highly advanced but also user-friendly, like a reliable alarm that detects potential issues before they escalate,” said Piyush Jain, Ph.D., an assistant professor at UF’s Department of Chemical Engineering, who is leading the research team. “This research is crucial given the staggering global impact of HIV and the critical need for early detection.” 

Related Links:
University of Florida


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.